These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 29678583)

  • 1. Identifying the SUMO1 modification of FAM122A leading to the degradation of PP2A-Cα by ubiquitin-proteasome system.
    Fan F; Zhao J; Liu Y; Zhao H; Weng L; Li Q; Chen G; Xu Y
    Biochem Biophys Res Commun; 2018 Jun; 500(3):676-681. PubMed ID: 29678583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FAM122A, a new endogenous inhibitor of protein phosphatase 2A.
    Fan L; Liu MH; Guo M; Hu CX; Yan ZW; Chen J; Chen GQ; Huang Y
    Oncotarget; 2016 Sep; 7(39):63887-63900. PubMed ID: 27588481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional Crosstalk between the PP2A and SUMO Pathways Revealed by Analysis of STUbL Suppressor, razor 1-1.
    Nie M; Arner E; Prudden J; Schaffer L; Head S; Boddy MN
    PLoS Genet; 2016 Jul; 12(7):e1006165. PubMed ID: 27398807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SUMO protease SENP1 deSUMOylates and stabilizes c-Myc.
    Sun XX; Chen Y; Su Y; Wang X; Chauhan KM; Liang J; Daniel CJ; Sears RC; Dai MS
    Proc Natl Acad Sci U S A; 2018 Oct; 115(43):10983-10988. PubMed ID: 30305424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sumoylation as a signal for polyubiquitylation and proteasomal degradation.
    Miteva M; Keusekotten K; Hofmann K; Praefcke GJ; Dohmen RJ
    Subcell Biochem; 2010; 54():195-214. PubMed ID: 21222284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination.
    Luo HB; Xia YY; Shu XJ; Liu ZC; Feng Y; Liu XH; Yu G; Yin G; Xiong YS; Zeng K; Jiang J; Ye K; Wang XC; Wang JZ
    Proc Natl Acad Sci U S A; 2014 Nov; 111(46):16586-91. PubMed ID: 25378699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FAM122A ensures cell cycle interphase progression and checkpoint control by inhibiting B55α/PP2A through helical motifs.
    Wasserman JS; Faezov B; Patel KR; Kurimchak AM; Palacio SM; Glass DJ; Fowle H; McEwan BC; Xu Q; Zhao Z; Cressey L; Johnson N; Duncan JS; Kettenbach AN; Dunbrack RL; Graña X
    Nat Commun; 2024 Jul; 15(1):5776. PubMed ID: 38982062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ubiquitin-proteasome system is a key component of the SUMO-2/3 cycle.
    Schimmel J; Larsen KM; Matic I; van Hagen M; Cox J; Mann M; Andersen JS; Vertegaal AC
    Mol Cell Proteomics; 2008 Nov; 7(11):2107-22. PubMed ID: 18565875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein Phosphatase Methyl-Esterase PME-1 Protects Protein Phosphatase 2A from Ubiquitin/Proteasome Degradation.
    Yabe R; Miura A; Usui T; Mudrak I; Ogris E; Ohama T; Sato K
    PLoS One; 2015; 10(12):e0145226. PubMed ID: 26678046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sumoylation and proteasomal activity determine the transactivation properties of the mineralocorticoid receptor.
    Tirard M; Almeida OF; Hutzler P; Melchior F; Michaelidis TM
    Mol Cell Endocrinol; 2007 Mar; 268(1-2):20-9. PubMed ID: 17314004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of the tumor suppressor PTEN by SUMO.
    González-Santamaría J; Campagna M; Ortega-Molina A; Marcos-Villar L; de la Cruz-Herrera CF; González D; Gallego P; Lopitz-Otsoa F; Esteban M; Rodríguez MS; Serrano M; Rivas C
    Cell Death Dis; 2012 Sep; 3(9):e393. PubMed ID: 23013792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the SUMO1 and ubiquitin conjugation pathways during the inhibition of proteasome activity with evidence of SUMO1 recycling.
    Bailey D; O'Hare P
    Biochem J; 2005 Dec; 392(Pt 2):271-81. PubMed ID: 16117725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SUMO modification of Akt regulates global SUMOylation and substrate SUMOylation specificity through Akt phosphorylation of Ubc9 and SUMO1.
    Lin CH; Liu SY; Lee EH
    Oncogene; 2016 Feb; 35(5):595-607. PubMed ID: 25867063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the Role of Paralog-Specific Sumoylation of HDAC1.
    Citro S; Chiocca S
    Methods Mol Biol; 2017; 1510():329-337. PubMed ID: 27761832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uncovering the SUMOylation and ubiquitylation crosstalk in human cells using sequential peptide immunopurification.
    Lamoliatte F; McManus FP; Maarifi G; Chelbi-Alix MK; Thibault P
    Nat Commun; 2017 Jan; 8():14109. PubMed ID: 28098164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CHFR is negatively regulated by SUMOylation-mediated ubiquitylation.
    Bae SJ; Kwon YE; Kim M; Seol JH
    Biochem Biophys Res Commun; 2013 Apr; 433(2):194-9. PubMed ID: 23454125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-canonical ubiquitin-based signals for proteasomal degradation.
    Kravtsova-Ivantsiv Y; Ciechanover A
    J Cell Sci; 2012 Feb; 125(Pt 3):539-48. PubMed ID: 22389393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SUMOylation of Blimp-1 promotes its proteasomal degradation.
    Shimshon L; Michaeli A; Hadar R; Nutt SL; David Y; Navon A; Waisman A; Tirosh B
    FEBS Lett; 2011 Aug; 585(15):2405-9. PubMed ID: 21722636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation.
    Tatham MH; Geoffroy MC; Shen L; Plechanovova A; Hattersley N; Jaffray EG; Palvimo JJ; Hay RT
    Nat Cell Biol; 2008 May; 10(5):538-46. PubMed ID: 18408734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SUMOylation attenuates the aggregation propensity and cellular toxicity of the polyglutamine expanded ataxin-7.
    Janer A; Werner A; Takahashi-Fujigasaki J; Daret A; Fujigasaki H; Takada K; Duyckaerts C; Brice A; Dejean A; Sittler A
    Hum Mol Genet; 2010 Jan; 19(1):181-95. PubMed ID: 19843541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.